These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 7927833)

  • 1. Bacterial resistance to fluoroquinolones: lessons to be learned.
    Ball P
    Infection; 1994; 22 Suppl 2():S140-7. PubMed ID: 7927833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of quinolone resistance.
    Wiedemann B; Heisig P
    Infection; 1994; 22 Suppl 2():S73-9. PubMed ID: 7927834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients.
    Naber KG; Witte W; Bauernfeind A; Wiedemann B; Wagenlehner F; Klare I; Heisig P
    Infection; 1994; 22 Suppl 2():S122-7. PubMed ID: 7927830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone resistance: mechanisms and epidemiology.
    Tillotson GS; Dorrian I; Blondeau J
    J Med Microbiol; 1997 Jun; 46(6):457-61. PubMed ID: 9379475
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V.
    Kresken M; Hafner D; Mittermayer H; Verbist L; Bergogne-Bérézin E; Giamarellou H; Esposito S; van Klingeren B; Kayser FH; Reeves DS
    Infection; 1994; 22 Suppl 2():S90-8. PubMed ID: 7927836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epidemiology of bacterial resistance to quinolones.
    Acar JF; O'Brien TF; Goldstein FW; Jones RN
    Drugs; 1993; 45 Suppl 3():24-8. PubMed ID: 7689447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of quinolone resistance. Eastern hemisphere.
    Turnidge J
    Drugs; 1995; 49 Suppl 2():43-7. PubMed ID: 8549389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of quinolone resistance: Europe and North and South America.
    Goldstein FW; Acar JF
    Drugs; 1995; 49 Suppl 2():36-42. PubMed ID: 8549361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures.
    Stein GE
    Pharmacotherapy; 2005 Oct; 25(10 Pt 2):44S-54S. PubMed ID: 16178675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing prevalence of antimicrobial resistance among organisms isolated from blood culture in a Singapore hospital.
    Kumarasinghe G; Chow C; Yin LH; Hong SY; Bassett DC
    Southeast Asian J Trop Med Public Health; 1994 Mar; 25(1):116-22. PubMed ID: 7825001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.
    Jones RN
    Am J Med; 1996 Jun; 100(6A):3S-12S. PubMed ID: 8678095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nosocomial outbreak of fluoroquinolone-resistant salmonella infection.
    Olsen SJ; DeBess EE; McGivern TE; Marano N; Eby T; Mauvais S; Balan VK; Zirnstein G; Cieslak PR; Angulo FJ
    N Engl J Med; 2001 May; 344(21):1572-9. PubMed ID: 11372008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.
    Maurin M; Abergel C; Raoult D
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2098-105. PubMed ID: 11408229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance patterns among nosocomial pathogens: trends over the past few years.
    Jones RN
    Chest; 2001 Feb; 119(2 Suppl):397S-404S. PubMed ID: 11171776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose intravenous fluoroquinolones in the treatment of severe infections.
    Modai J
    J Chemother; 1999 Dec; 11(6):478-85. PubMed ID: 10678789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.
    Paton JH; Reeves DS
    Drugs; 1988 Aug; 36(2):193-228. PubMed ID: 3053126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action and resistance of older and newer fluoroquinolones.
    Hooper DC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.